Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

Cell Therapeutics reports financial results for the third quarter and nine months ended September 30, 2009

Cell Therapeutics, Inc. today reported recent achievements and financial results for the third quarter and nine months ended September 30, 2009, which included a 45% decrease in the net loss attributable to common shareholders for the nine month period in 2009 compared to the same period in 2008.

5 Nov 2009

FDA approves SPA Protocol Amendment for Lucanix Phase III clinical trial

NovaRx Corporation announced today that the Company has successfully negotiated and received FDA approval for a Special Protocol Assessment (SPA) Protocol Amendment to the pivotal Lucanix® Phase III clinical trial in patients with Non-Small Cell Lung Cancer (NSCLC).

4 Nov 2009

Non-small cell lung cancer patients who undergo PCI decrease their risk of developing brain metastases

Patients with non-small cell lung cancer treated with preventative brain radiation (called prophylactic cranial irradiation or PCI), significantly decrease their risk of developing brain metastases (cancer spread in the brain) by more than 50 percent (from 18 percent to 8 percent), compared to those who did not receive the treatment, according to a randomized study presented at the plenary session November 2, 2009, at the 51st Annual Meeting of American Society for Radiation Oncology (ASTRO).

4 Nov 2009

Combination of high-dose radiotherapy and chemotherapy shows encouraging results in treating LSCL

Treating limited stage small cell lung cancer(LSCL) with a combination of accelerated high-dose radiotherapy and chemotherapy has shown encouraging results, opening the door to larger scale investigation, according to new research from The University of Texas M. D. Anderson Cancer Center.

4 Nov 2009

PET imaging is not the basis for increasing dosage level

Positron emission tomography (PET) imaging of non-small cell lung cancer prior to receiving radiation therapy should not be the basis for determining areas that may benefit from higher doses of radiation, according to research presented by investigators at Thomas Jefferson University Hospital at the 51st ASTRO Annual Meeting (Abstract #2583/B-186).

4 Nov 2009

SBRT stops the growth of cancer for 98% of patients with NSCLC

Stereotactic body radiation therapy (SBRT) stopped the growth of cancer at its original site in the lung for three years among nearly 98 percent of patients with early non-small cell lung cancer (NSCLC) who are unable to have the cancer surgically removed, according to an updated three-year study presented November 2, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO).

3 Nov 2009

New study to assess preventative brain radiation therapy for lung cancer patients

A new study is taking a closer look at the benefits versus risks for lung cancer patients to undergo preventative brain radiation therapy as a means to stop cancer from spreading to the brain.

3 Nov 2009

Patients with non-small cell lung cancer treated with PCI decrease their risk of developing brain metastases

3 Nov 2009

Intervals between lung cancer diagnosis and treatment may attribute to health care discrepancies

Research published in the November 2009 issue of the Journal of Thoracic Oncology has found that intervals between lung cancer suspicion, diagnosis and treatment may be attributed to health care system discrepancies.

2 Nov 2009

BHGI's approach to cancer treatment guidelines for low- and moderate-income countries

When the prestigious British medical journal The Lancet Oncology this week published six cancer treatment guideline papers aimed at the resource-diverse nations of Asia, it used as its model the economic template developed by the Breast Health Global Initiative (BHGI) based at Fred Hutchinson Cancer Research Center.

31 Oct 2009

Eisai reports global Phase III study results of eribulin mesylate

Eisai Inc. today announced preliminary results from a recently completed Phase III study with eribulin mesylate (E7389), discovered and developed by the company, in patients with locally advanced or metastatic breast cancer.

30 Oct 2009

ASTRO to host news briefings on top cancer research papers

The American Society for Radiation Oncology (ASTRO) will host four news briefings with accompanying live webcasts on the top cancer research papers from its 51st Annual Meeting.

30 Oct 2009

Fiscal 2009 results announced by Helix BioPharma

Helix BioPharma Corp. today announced financial results for the year ended July 31, 2009.

30 Oct 2009

Celera to use Medical Therapies' midkine patent portfolio for development of novel lung cancer diagnostics

Celera Corporation, a health care company focused on genetics, and Medical Therapies Limited (ASX:MTY), a biotechnology company developing midkine-related diagnostic and therapeutic products, have entered into an exclusive license agreement for the use of MTY’s midkine patent portfolio for the development of novel lung cancer diagnostics.

30 Oct 2009

Highlights of new cancer research to be presented at 51st ASTRO Annual Meeting

The following are highlights of new cancer research being presented at the American Society for Radiation Oncology's (ASTRO) 51st Annual Meeting on November 1-5, 2009, in Chicago.

29 Oct 2009

Bcl-2 inhibitor may enhance chemotherapy treatment in patients with prostate cancer

In trying to better predict a patient's response to chemotherapy for cancer treatment, a team of investigators at The Cancer Institute of New Jersey (CINJ) and Rutgers, The State University of New Jersey, has identified a way to better manipulate a gene product to cause cancer cells to die.

28 Oct 2009

Hope for lung cancer patients

Lung cancer is the world's most common cancer, and an estimated 219,440 Americans are expected to be diagnosed this year. It is also estimated that lung cancer will cause 159,000 deaths in the United States this year - more than the total number of deaths resulting from breast, colon and prostate cancers combined.

27 Oct 2009

BioMarin Pharmaceutical announces the acquisition of Huxley Pharmaceuticals

BioMarin Pharmaceutical Inc. announced today that it has acquired Huxley Pharmaceuticals, Inc. (Huxley), which has rights to a proprietary form of 3,4-diaminopyridine (3,4-DAP), amifampridine phosphate, for the rare autoimmune disease Lambert Eaton Myasthenic Syndrome (LEMS).

27 Oct 2009

Rosetta Genomics, GTG sign exclusive distribution agreement

Rosetta Genomics, Ltd., a leading developer of microRNA-based molecular diagnostics, and Genetic Technologies Limited (GTG), the leading private genetic testing laboratory in Australia, announced today the signing of an exclusive distribution agreement for Rosetta Genomics’ three currently available diagnostic tests.

22 Oct 2009

Celgene announces fiscal 2009 third-quarter results

Celgene Corporation announced non-GAAP (Generally Accepted Accounting Principles) net income of $259.8 million, or non-GAAP earnings per diluted share of $0.56 for the quarter ended September 30, 2009. Non-GAAP net income for the third quarter of 2008 was $185.9 million, or non-GAAP earnings per diluted share of $0.40.

22 Oct 2009

Small Cell Lung Cancer News and Research

Cell Therapeutics reports financial results for the third quarter and nine months ended September 30, 2009

FDA approves SPA Protocol Amendment for Lucanix Phase III clinical trial

Non-small cell lung cancer patients who undergo PCI decrease their risk of developing brain metastases

Combination of high-dose radiotherapy and chemotherapy shows encouraging results in treating LSCL

PET imaging is not the basis for increasing dosage level

SBRT stops the growth of cancer for 98% of patients with NSCLC

New study to assess preventative brain radiation therapy for lung cancer patients

Patients with non-small cell lung cancer treated with PCI decrease their risk of developing brain metastases

Intervals between lung cancer diagnosis and treatment may attribute to health care discrepancies

BHGI's approach to cancer treatment guidelines for low- and moderate-income countries

Eisai reports global Phase III study results of eribulin mesylate

ASTRO to host news briefings on top cancer research papers

Fiscal 2009 results announced by Helix BioPharma

Celera to use Medical Therapies' midkine patent portfolio for development of novel lung cancer diagnostics

Highlights of new cancer research to be presented at 51st ASTRO Annual Meeting

Bcl-2 inhibitor may enhance chemotherapy treatment in patients with prostate cancer

Hope for lung cancer patients

BioMarin Pharmaceutical announces the acquisition of Huxley Pharmaceuticals

Rosetta Genomics, GTG sign exclusive distribution agreement

Celgene announces fiscal 2009 third-quarter results

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News